# Primary Skeletal Muscle Lymphoma Presenting as Acute Compartment Syndrome of the Forearm: A Case Report

**Authors:** Kazuhiro Ikeda, Hiromitsu Tsuge, Sho Kohyama, Naoya Kikuchi, Takaji Yanai

PMC · DOI: 10.7759/cureus.93706 · Cureus · 2025-10-02

## TL;DR

A rare case of lymphoma in the forearm muscle presented as compartment syndrome and was successfully treated with chemotherapy.

## Contribution

This case report highlights the importance of tissue sampling during fasciotomy for rapid diagnosis of primary skeletal muscle lymphoma.

## Key findings

- Diffuse large B-cell lymphoma presented as acute compartment syndrome in a 70-year-old woman.
- R-CHOP chemotherapy reduced symptoms and EPOCH-R achieved complete remission.
- No recurrence or limb-related complications occurred over four years of follow-up.

## Abstract

Primary skeletal muscle lymphoma rarely causes compartment syndrome. We encountered a case of diffuse large B-cell lymphoma that presented as acute compartment syndrome. A 70-year-old woman developed subacute swelling and pain in the left forearm without an identifiable cause. Compartment pressures were markedly elevated at 110 mmHg in the dorsal and 125 mmHg in the deep volar compartments. Despite emergent fasciotomy, her symptoms continued to progress. Intraoperative muscle biopsy revealed diffuse large B-cell lymphoma with overexpression of MYC and BCL2. After the initiation of R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) chemotherapy, the forearm swelling and pain subsided, and the fasciotomy wound was managed conservatively until closure. Because of the high-risk double-expressor profile, the regimen was escalated to EPOCH-R (Etoposide, Prednisone, Oncovin (Vincristine), Cyclophosphamide, hydroxydaunorubicin (Doxorubicin), and Rituximab), and six courses achieved complete remission. The patient experienced no recurrence during four years of follow-up and developed no sequelae related to compartment syndrome. This case highlights the importance of rapid diagnosis through tissue sampling at the time of fasciotomy. Prompt initiation of chemotherapy is directly linked to both survival and preservation of limb function.

## Linked entities

- **Genes:** MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609], BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596]
- **Chemicals:** Cyclophosphamide (PubChem CID 2907), Doxorubicin (PubChem CID 31703), Vincristine (PubChem CID 5978), Prednisone (PubChem CID 5865), Etoposide (PubChem CID 36462), Oncovin (PubChem CID 249332), hydroxydaunorubicin (PubChem CID 31703)
- **Diseases:** diffuse large B-cell lymphoma (MONDO:0018905), compartment syndrome (MONDO:0004001)

## Full-text entities

- **Genes:** MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}
- **Diseases:** swelling (MESH:D004487), compartment syndrome (MESH:D003161), pain (MESH:D010146), Primary Skeletal Muscle Lymphoma (MESH:D008223), diffuse large B-cell lymphoma (MESH:D016403), Acute Compartment Syndrome (MESH:D000208)
- **Chemicals:** Cyclophosphamide (MESH:D003520), Oncovin (MESH:D014750), Rituximab (MESH:D000069283), Prednisone (MESH:D011241), EPOCH-R (-), Doxorubicin (MESH:D004317), Etoposide (MESH:D005047)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12579514/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12579514/full.md

## References

15 references — full list in the complete paper: https://tomesphere.com/paper/PMC12579514/full.md

---
Source: https://tomesphere.com/paper/PMC12579514